Online inquiry

IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2981MR)

This product GTTS-WQ2981MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL33 gene. The antibody can be applied in Esophagitis eosinophilic research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001199640.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 90865
UniProt ID O95760
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ2981MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4308MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ2537MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ12039MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ3611MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ785MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Ab-2
GTTS-WQ3479MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BA1126
GTTS-WQ9387MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ8338MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HN-66000
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW